| oxaliplatin / Generic mfg. |
NCT01889680: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | 5-FU, 5-fluorouracil, LV, leucovorin, ziv-aflibercept, mFOLFOX6, 5-FU plus leucovorin plus oxaliplatin | NSABP Foundation Inc, Sanofi | Colorectal Cancer, Metastatic Colorectal Cancer | 05/16 | 05/18 | | |
NCT01888978: Molecularly Tailored Therapy for Pancreas Cancer |
|
|
| Completed | 2 | 19 | US | Gem-OX, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Gem-5FU, 5-FU, 5-fluorouracil, Gem-Tax, Docetael, taxotere, Modified FOLFOX-6, 5-Fluorourcil, Leucovorin, Ox-Tax, Docetaxel, Taxotere, Oxalipaltin, FOLFIRI, Irinotecan, CPT-11, 5-Fluorouracil, Tax-Iri | Georgetown University | Pancreatic Cancer | 06/16 | 01/18 | | |
NCT02243007: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer |
|
|
| Terminated | 2 | 7 | US | FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation therapy, Capecitabine, Xeloda | Massachusetts General Hospital | Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma | 06/16 | 06/16 | | |
NCT02527785: Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer |
|
|
| Completed | 2 | 44 | RoW | Oxaliplatin, Irinotecan, S-1(OIS), Liplatin, Inotecan, TS-1 (tegafur, gimeracil, oteracil) | Hallym University Medical Center, Jeil Pharmaceutical Co., Ltd. | Stomach Neoplasm | 06/16 | 04/17 | | |
NCT00571740: Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | bevacizumab, cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | | | | |
NCT01283204: Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer |
|
|
| Completed | 2 | 180 | RoW | SP, TS-1® with Cisplatin, FL/Tax, Paclitaxel with Leucovorin with 5-FU, FL/Doc, Docetaxel with Leucovorin with 5-FU, FOLFOX, Oxaliplatin with Leucovorin with 5-FU | Yonsei University | Recurrent or Metastatic Gastric Cancer | 07/16 | 07/16 | | |
NCT02984501: Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 41 | Europe | Radiation, Neoadjuvant therapy, Chemotherapy, Induction therapy | Campus Bio-Medico University | Pancreatic Cancer | 08/16 | 08/16 | | |
NCT02085005: Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669 | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/16 | 08/16 | | |
NCT01688336: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer |
|
|
| Terminated | 2 | 9 | US | FOLFIRINOX, FOLFIRINOX is a chemotherapy regimen comprised of the following drugs, given in combination, -Oxaliplatin, -Leucovorin, -Irinotecan, -5FU | UNC Lineberger Comprehensive Cancer Center | Pancreatic Cancer | 08/16 | 11/16 | | |
| Completed | 2 | 59 | Europe | Cetuximab, Erbitux® | Martin Schuler, Prof. Dr. med. | Metastatic Colorectal Cancer | 09/16 | 09/16 | | |
|
|
| Completed | 2 | 250 | Europe | Oxaliplatin, 5FU/LV, Bevacizumab, Bevacizumab, Oxaliplatin, I-LV, 5-FU, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan, Irinotecan | Martin-Luther-Universität Halle-Wittenberg, Roche Pharma AG | Metastatic Colorectal Cancer | 09/16 | 08/18 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
PACOX, NCT02089633: Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC |
|
|
| Completed | 2 | 17 | RoW | PACOX, PEG-BCT-100, Xeloda, Eloxatin | Bio-Cancer Treatment International Limited, The University of Hong Kong | Hepatocellular Carcinoma | 09/16 | 10/16 | | |
NCT03048123: HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B |
|
|
| Completed | 2 | 79 | RoW | Hepatic arterial infusion, Transarterial chemoembolization, Folfox Protocol, Folfox for TAI, TACE Drug Protocol, Drugs for transarterial chemotherapy and embolization | Sun Yat-sen University | Hepatocellular Carcinoma | 10/16 | 01/17 | | |
NCT02035072 / 2010-020379-22: Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. |
|
|
| Completed | 2 | 40 | Europe | Gemcitabine, Oxaliplatin, oxalipaltin, Hypofractionated RT | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer | 12/16 | 12/16 | | |
Be TRI, NCT02246049: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC |
|
|
| Completed | 2 | 69 | Japan | Bevacizumab, BV, 5-fluorouracil, 5-FU, Irinotecan hydrochloride, CPT-11, Leucovorin calcium, I-LV, Oxaliplatin, L-OHP | EPS Corporation | Colorectal Neoplasms | 02/17 | 02/17 | | |
NCT02195180 / 2013-004262-34: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma |
|
|
| Completed | 2 | 141 | Europe | ERY001, L asparaginase encapsulated in erythrocytes, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox) | ERYtech Pharma | Pancreatic Adenocarcinoma Metastatic | 02/17 | 11/17 | | |
| Completed | 2 | 90 | Europe | DOX 4 cycles - Surgery, DOX 2 cycles - Surgery - DOX 2 cycles | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Gastric Cancer, Locally Advanced Malignant Neoplasm | 03/17 | 03/17 | | |
| Completed | 2 | 232 | Europe | Maintenance:BEVACIZUMAB, Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE | Azienda Ospedaliero, Universitaria Pisana | Metastatic Colorectal Cancer | 03/17 | 09/17 | | |
ATOM, NCT01836653: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
|
|
| Completed | 2 | 122 | Japan | Bevacizumab, Avastin, Cetuximab, Erbitux, L-OHP, Oxaliplatin, l-LV, Levofolinate, 5-FU, Fluorouracil | EPS Corporation | Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer | 03/17 | 03/17 | | |
NCT02241551: Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer |
|
|
| Terminated | 2 | 2 | US | gemcitabine/nab-paclitaxel, Gemzar, ABRAXANE, mFOLFIRINOX, irinotecan, fluorouracil, oxaliplatin | Nathan Bahary, MD | Borderline Resectable Pancreatic Cancer | 03/17 | 03/17 | | |
NCT02981498: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma |
|
|
| Completed | 2 | 35 | RoW | Hepatic arterial infusion chemotherapy, Folfox Protocol | Sun Yat-sen University | Hepatocellular Carcinoma | 04/17 | 04/17 | | |
NCT02026583: A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients |
|
|
| Completed | 2 | 43 | RoW | Simvastatin | Samsung Medical Center | Colorectal Cancer | 04/17 | 04/17 | | |
TRUST, NCT03085992: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer |
|
|
| Completed | 2 | 49 | Europe | FOLFOXIRI plus Bevacizumab, Chemoradiotherapy plus Bevacizumab | Azienda Ospedaliero, Universitaria Pisana | Rectal Cancer | 07/17 | 03/18 | | |
NCT02015169: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis |
|
|
| Completed | 2 | 32 | RoW | Lapatinib, Tykerb, GSK | Samsung Medical Center | HER2-positive Gastric Cancer Patients With Liver Metastasis | 07/17 | 11/17 | | |
NCT02558868: Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer |
|
|
| Completed | 2 | 80 | RoW | Irinotecan, Oxaliplatin | Zhejiang University | Pancreatic Neoplasms | 09/17 | 12/17 | | |
FOXAGAST, NCT02486601: NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma |
|
|
| Unknown status | 2 | 55 | Europe | nab-paclitaxel, ABRAXANE, FOLFOX | GERCOR - Multidisciplinary Oncology Cooperative Group, Celgene Corporation | Cancer of Stomach | 10/17 | 06/22 | | |
PRIMIER, NCT02413853: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | CBP/beta-catenin Antagonist PRI-724, PRI-724, Wnt signaling pathway inhibitor PRI-724, Bevacizumab, Avastin, rhuMab-VEGF, Leucovorin Calcium, CF, Oxaliplatin, Fluorouracil, Laboratory Biomarker Analysis | University of Southern California, National Cancer Institute (NCI), Prism Pharma Co., Ltd. | Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer | 11/17 | 11/18 | | |
ALEXANDRIA, NCT02654639: Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | TAS-102, Lonsurf, Avastin, Bevacizumab | Georgetown University | Metastatic Colorectal Cancer | 11/17 | 11/17 | | |
| Completed | 2 | 75 | Europe | Pazopanib, 5-FU, Oxaliplatin, Leukovorin (FLO) | Charite University, Berlin, Germany | Advanced Gastric Cancer | 12/17 | 12/17 | | |
|
NCT02079220: A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Arm A, Xeloda, ELOXATIN, ZALTRAP, Arm B | James J Lee, Sanofi | Metastatic Colorectal Cancer | 03/18 | 03/18 | | |
POLAF, NCT02970916 / 2016-001508-45: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms |
|
|
| Completed | 2 | 100 | Europe | FOLFIRI+aflibercept | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi | Metastatic Colorectal Cancer | 05/18 | 12/18 | | |
IXOGoo1, NCT01129310: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. |
|
|
| Completed | 2 | 47 | Canada | Irinotecan-Capecitabine-Oxaliplatin, Camptosar; Xeloda; Eloxatin | AHS Cancer Control Alberta, Sanofi | Gastrointestinal Neoplasm, Gastric Adenocarcinoma | 05/18 | 05/18 | | |
| Terminated | 2 | 20 | Europe | S-1, Teysuno, tegafur/gimeracil/oteracil, Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Heikki Joensuu | Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer, Rectum Cancer | 08/18 | 08/18 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT02943603: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach |
|
|
| Withdrawn | 2 | 0 | US | mFLOFOX6 + pembrolizumab | Weijing Sun, MD, FACP | Adenocarcinoma, Stomach Cancer | 01/19 | 07/19 | | |
NCT02942563: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-FU, Capecitabine | RenJi Hospital | Rectal Cancer | 09/19 | 09/22 | | |
REALIZATION, NCT02404753: A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy |
|
|
| Active, not recruiting | 2 | 102 | RoW | Neoadjuvant Chemotherapy, NACT, Laparoscopic gastrectomy, LDG, Open gastrectomy, ODG, Adjuvant Chemotherapy, ACT | Peking University, Beijing Municipal Science & Technology Commission | Gastric Cancer | 11/20 | 11/22 | | |
NCT02510378: Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases |
|
|
| Recruiting | 2 | 47 | RoW | Short course radiotherapy | Chinese Academy of Medical Sciences | Stage IV Rectal Cancer, Liver Metastasis, Resectable | 12/20 | 12/22 | | |
| Recruiting | 2 | 100 | Europe | Bevacizumab plus alternating Xelox/Xeliri, Avastin, Xeloda, irinotecan, oxaliplatin | Pia Osterlund | Metastatic Colorectal Cancer | 12/25 | 12/25 | | |
NCT00625651: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer |
|
|
| Completed | 1b/2 | 202 | US | Placebo, AMG 655, Modified FOLFOX6, mFOLFOX6, Bevacizumab | Amgen | Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer | 08/10 | 09/11 | | |
NCT00005050: Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | | US | ethynyluracil, fluorouracil, oxaliplatin | NYU Langone Health, National Cancer Institute (NCI) | Colorectal Cancer | 06/01 | | | |
NCT00049101: Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | | US | erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer | | 08/04 | | |
NCT00055822: Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 16 | US | oblimersen sodium, fluorouracil, leucovorin calcium, oxaliplatin | The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI) | Colorectal Cancer | 10/04 | 10/04 | | |
NCT00403624: Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer |
|
|
| Completed | 1/2 | 38 | Europe | OXALIPLATIN | Sanofi | Rectal Neoplasms | 11/05 | 11/05 | | |
NCT00087334: Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 1/2 | 10 | US | capecitabine, gefitinib, oxaliplatin | Roswell Park Cancer Institute | Colorectal Cancer | 11/05 | | | |
NCT00242190: Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer |
|
|
| Completed | 1/2 | 40 | US | oxaliplatin, gemcitabine, radiation therapy | University of Michigan Rogel Cancer Center, Sanofi-Synthelabo | Pancreatic Neoplasms | 03/06 | 02/10 | | |
NCT00093652: Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer |
|
|
| Terminated | 1/2 | | US | gefitinib, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy | Roswell Park Cancer Institute | Esophageal Cancer | 05/06 | | | |
| Terminated | 1/2 | 46 | Europe | Oxaliplatin | Sanofi | Rectal Neoplasms | 06/06 | | | |
NCT00006094: Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum |
|
|
| Completed | 1/2 | 24 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, external beam radiation therapy, EBRT | National Cancer Institute (NCI) | Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer | 10/06 | | | |
NCT00086931: Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum |
|
|
| Completed | 1/2 | 37 | US | capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy | Roswell Park Cancer Institute | Colorectal Cancer | 05/07 | 05/10 | | |
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer |
|
|
| Completed | 1/2 | 106 | Europe | oxaliplatin, capecitabine, radiotherapy | Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo | Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer | 07/07 | 07/09 | | |
NCT00291785: Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer |
|
|
| Completed | 1/2 | 48 | Europe | CT-2106, Folinic acid, 5-FU (fluorouracil) | CTI BioPharma | Colorectal Cancer | 08/07 | 09/08 | | |
SAKK 41/03, NCT00217711: Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 1/2 | 23 | Europe | Capecitabine, irinotecan hydrochloride, oxaliplatin | Swiss Group for Clinical Cancer Research | Colorectal Cancer | 08/07 | 10/11 | | |
NCT00307723: Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer |
|
|
| Terminated | 1/2 | 52 | US | bevacizumab, 5-Fluorouracil, Oxaliplatin, gemcitabine, External Beam Radiation Therapy | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Genentech, Inc., Sanofi | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | 08/07 | 07/09 | | |
NCT00226941: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
|
|
| Terminated | 1/2 | 23 | US | Cetuximab, Erbitux, C225, IMC-C225, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT, Diphenhydramine hydrochloride (HCl), Benadryl, Unisom, Sominex | George Albert Fisher, Bristol-Myers Squibb | Rectal Cancer, Colo-rectal Cancer | 03/08 | 02/09 | | |
NCT00531245: A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 77 | RoW | TS-1, oxaliplatin | Samsung Medical Center | Colorectal Neoplasms | 06/08 | 03/09 | | |
NCT00422773: Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 21 | Europe | Cetuximab, Cetuximab (C225, Erbitux by Merck) | Technische Universität Dresden | Metastatic Colorectal Cancer | 06/08 | | | |
|
NCT00345761: Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer |
|
|
| Completed | 1/2 | 64 | Japan | Bevacizumab, Oxaliplatin, Capecitabine | Chugai Pharmaceutical, Yakult Honsha Co., LTD | Colorectal Cancer | 10/08 | 07/10 | | |
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 12 | US | lapatinib, oxaliplatin, capecitabine | GlaxoSmithKline | Neoplasms, Colorectal | 10/08 | 10/08 | | |
NCT00711243: Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor |
|
|
| Completed | 1/2 | 59 | US | docetaxel, fluorouracil, oxaliplatin | Northwestern University, National Cancer Institute (NCI) | Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 12/08 | 02/11 | | |
| Completed | 1/2 | 46 | Europe | gemcitabine, oxaliplatin, capecitabine | University Hospital, Basel, Switzerland, Swiss National Science Foundation, Swiss Cancer League, Roche Pharma AG, Sanofi | Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | 02/09 | 12/09 | | |
|
|
NCT00494221: A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX |
|
|
| Completed | 1/2 | 172 | Japan | AZD2171, cediranib, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Eloxatin®, 5-FU, Leucovorin, Placebo Cediranib | AstraZeneca | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
SCI-101, NCT01110941: Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China |
|
|
| Completed | 1/2 | 20 | RoW | S-1, leucovorin, oxaliplatin, S-1(20mg、25mg)--Taiho Pharmaceutical Co., Ltd.；, LV (25 mg)；, L-OHP (50 mg)--Sanofi Aventis Co., Ltd. | Shen Lin, 307 Hospital of PLA, Beijing Union Hosptial, Tianjin Medical University Cancer Institute and Hospital, Hebei Provincial Cancer Hospital | Colorectal Cancer | 03/10 | 10/10 | | |
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Terminated | 1/2 | 9 | US | docetaxel, oxaliplatin, vandetanib, placebo | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 06/10 | | | |
|
NCT00463840: Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer |
|
|
| Terminated | 1/2 | 24 | US | Oxaliplatin, Oxaliplatin: Eloxatin, 5FU, 5-Fluorouracil, Radiation, Surgery, FOLFOX 6 | NYU Langone Health, Sanofi | Pancreatic Cancer | 07/10 | 10/15 | | |
| Completed | 1/2 | 51 | Europe | Oxaliplatin, Capecitabine, Bevacizumab, Imatinib, Xeloda, Avastin, Imatinib, Eloxatin | University of Cologne, Roche Pharma AG, Novartis, Sanofi | Stage IV Colorectal Cancer | 08/10 | 12/12 | | |
|
NCT00228189: Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients |
|
|
| Completed | 1/2 | 30 | Europe | CEA-loaded dendritic cell vaccine | Radboud University Medical Center | Colorectal Cancer, Liver Metastases | 11/10 | 11/10 | | |
IMA910-101, NCT00785122 / 2007-005666-12: IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy |
|
|
| Completed | 1/2 | 92 | Europe, RoW | Endoxana, Leukine, IMA910, Endoxana (Cyclophosphamide), Aldara (Imiquimod), IMA910, GM-CSF, Endoxana, Leukine, IMA910, Aldara | Immatics Biotechnologies GmbH | Colorectal Carcinoma | 01/11 | 05/13 | | |
NCT00809796: A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment |
|
|
| Completed | 1/2 | 15 | Canada | pentamidine | Oncozyme Pharma Inc. | Colorectal Cancer | 05/11 | 06/11 | | |
EOXP, NCT00667420: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma |
|
|
| Terminated | 1/2 | 17 | US | panitumumab, epirubicin, oxaliplatin, xeloda | Massachusetts General Hospital | Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 06/11 | 06/14 | | |
POXX, NCT00578071: Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer |
|
|
| Completed | 1/2 | 29 | US | Panitumumab, Capecitabine, Xeloda, Oxaliplatin, Radiation Therapy (RT) | Brian Czito, Amgen | Cancer of the Esophagus | 07/11 | 06/12 | | |
NCT00819754: A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 1/2 | 23 | Canada | IXO regimen + bevacizumab, irinotecan - Camptosar, capecitabine - Xeloda, Oxaliplatin - Eloxatin, bevacizumab - Avastin | Ottawa Hospital Research Institute, Hoffmann-La Roche, Pfizer, Sanofi, Ottawa Regional Cancer Foundation | Metastatic Colorectal Cancer | 02/12 | 05/12 | | |
|
NCT01042028: A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer |
|
|
| Terminated | 1/2 | 39 | Europe | Everolimus, Cetuximab, Irinotecan, RAD001, Capecitabine, Oxaliplatine, Xeloda, Eloxatin | Per Pfeiffer, Odense University Hospital, Aarhus University Hospital | Pancreatic Cancer | 11/12 | 01/14 | | |
|
|
NCT00374985: Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction |
|
|
| Completed | 1/2 | 25 | Europe | Docetaxel, Oxaliplatin, Radiotherapy | Johannes Gutenberg University Mainz | Esophageal Neoplasms, Stomach Neoplasms | 09/13 | 09/13 | | |
NCT02048540: Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell |
|
|
| Completed | 1/2 | 86 | RoW | Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy | Chinese PLA General Hospital | Locally Advanced Gastric Carcinoma | 12/13 | 12/13 | | |
NCT00955721: A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer |
|
|
| Terminated | 1/2 | 9 | US | Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Sorafenib, BAY 43-9006 | University of Miami | Cholangiocarcinoma, Biliary Tract Cancer, Gallbladder Cancer | 07/14 | 07/14 | | |
NCT01955629 / 2013-000858-22: Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient |
|
|
| Terminated | 1/2 | 4 | Europe | Aflibercept AVE0005, Zaltrap, Oxaliplatin, Eloxatin, SR96669, Capecitabine | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 03/15 | 03/15 | | |
NCT00526110: Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients |
|
|
| Completed | 1/2 | 98 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Docetaxel, Taxotere, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Diseases | 06/15 | 06/15 | | |
NCT01632306: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer |
|
|
| Terminated | 1/2 | 13 | US | LY2090314, FOLFOX, FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), Gemcitabine, Gemzar, LY188011, Nab-paclitaxel | Eli Lilly and Company, Mayo Clinic | Pancreatic Cancer | 06/15 | 06/15 | | |
| Withdrawn | 1/2 | 0 | US | Oxaliplatin (via HAI), 5 Fluorouracil (systemic) | Medical College of Wisconsin | Colorectal Cancer, Metastasis, Liver Cancer | 08/15 | 08/15 | | |
NCT01047293: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma |
|
|
| Completed | 1/2 | 47 | US | RAD001, everlomius, FOLFOX, oxaliplatin + 5 FU + leucovorin, Bevacizumab, Avastin | University of Utah, Novartis | Colorectal Cancer | 08/15 | 08/15 | | |
|
NabucCO, NCT02109341: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer |
|
|
| Completed | 1/2 | 148 | Europe | Paclitaxel bound albumine, nab-paclitaxel | Gruppo Oncologico Italiano di Ricerca Clinica | Metastatic Pancreatic Cancer | 12/15 | 01/16 | | |
NCT01231399: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer |
|
|
| Completed | 1/2 | 6 | US | fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Adrucil, Efudex, FU, leucovorin calcium, calcium folinate, CF, CFR, citrovorum factor, LV, Wellcovorin, oxaliplatin, 1-OHP, Dacotin, Dacplat, diaminocyclohexane oxalatoplatinum, Eloxatin, L-OHP, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling | City of Hope Medical Center, National Cancer Institute (NCI) | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer | 07/16 | 07/16 | | |
|
NCT01975454: Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 62 | RoW | Chemotherapy, Oxaliplatin, Capecitabine, Herbal therapy, Traditional Chinese Medicine | Shanghai University of Traditional Chinese Medicine, Chongqing Three Gorges Central Hospital | Metastatic Colorectal Cancer | 09/16 | 12/17 | | |
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma |
|
|
| Completed | 1/2 | 154 | Europe | Nab-paclitaxel, Abraxane | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation | Esophageal Cancer, Toxicity | 03/17 | 03/17 | | |
NCT01206530: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer |
|
|
| Completed | 1/2 | 50 | US | Hydroxychloroquine, Oxaliplatin, Leucovorin, 5-fluorouracil, Bevacizumab | Abramson Cancer Center of the University of Pennsylvania | Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma | 09/17 | 09/17 | | |
NCT01490749: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer |
|
|
| Completed | 1/2 | 17 | US | RAD001, Everolimus, XELOX, Oxaliplatin and capecitabine, Eloxatin and Xeloda, Carboplatin, Paraplatin, Radiation | Emory University, Novartis | Esophageal Cancer, Neoplasms, Esophageal | 02/19 | 02/19 | | |
NCT02575508: Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer |
|
|
| Withdrawn | 1/2 | 0 | US | Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, U-101440E, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, pan FGFR Kinase Inhibitor BGJ398, BGJ398, Pharmacological Study | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 05/20 | | | |
HyRec, NCT01716949: Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer |
|
|
| Recruiting | 1/2 | 59 | Europe | Radiotherapy, Hyperthermia, 5-Fluorouracil, all brands of 5-Fluorouracil are allowed, Capecitabine, all brands of Capecitabine are allowed, Oxaliplatin, all brands of oxaliplatin are allowed | University of Erlangen-Nürnberg Medical School | Rectal Cancer | 06/22 | 06/23 | | |
